Occurrence and isotype of antibodies against peripheral nerve myelin in serum from patients with peripheral neuropathy and healthy controls

MABEL CRUZ,* JAN ERNERUDH,† TOMAS OLSSON,* BO HÖJEBERG,*
HANS LINK*

From the Department of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm,* and Department of Neurology, Linköping University Hospital, Linköping, Sweden

SUMMARY Antibodies against peripheral nerve myelin have previously been demonstrated in serum from patients with peripheral neuropathy and IgM paraproteinaemia, and a causal relationship has been suggested. Using enzyme-linked immunosorbent assay (ELISA), anti-myelin antibodies were found in sera from eight of 16 patients with polyneuropathy and paraproteinaemia, but also in 17% of 109 patients with peripheral neuropathy lacking monoclonal immunoglobulin, including five of 10 patients with Charcot-Marie-Tooth disease, and in 16% of 142 blood donors. The antibodies were mostly of IgM class in the two neuropathy groups, while blood donors had mostly IgA antibodies, and a few subjects of each group had anti-myelin antibodies of two different isotypes. Western blot confirmed the ELISA results in a majority of antibody positive sera and revealed a 25–30 kD myelin target antigen for sera from the three groups, and for some of the non-paraproteinaemic sera also a 100 kD myelin target antigen. Our results demonstrate that the presence of serum autoantibodies against peripheral nerve myelin does not necessarily indicate a pathological event.

There is an association between polyneuropathy and monoclonal gammapathies.1 A causal relationship between IgM M-component in serum and polyneuropathy has been suggested.2 Recent reports of delayed appearance in serum of IgM M-component in a patient with polyneuropathy and antibody binding to peripheral nerve,3 and the presence of antibodies against myelin associated glycoprotein in a patient with polyneuropathy lacking M-component in serum4 have suggested that antibodies against myelin may also be of importance in polyneuropathy patients without demonstrable M-component in serum, and that it might be worth searching for such antibodies in any patient with polyneuropathy. However, in our opinion the significance of antibodies against peripheral nerve myelin (PNM) is not clear, since previous studies have included, as negative controls, pooled normal serum, serum IgM M-components from patients without polyneuropathy, or samples from only a few healthy individuals. Thus, the extent to which such autoantibodies are found in healthy subjects is not known with certainty. Evidence of the presence of anti-myelin antibodies in serum from healthy subjects has in fact recently been presented.5

We now report frequencies and isotypes of antibodies to PNM in sera from patients with peripheral neuropathy subgrouped according to the presence or absence of serum M-component and also in sera from blood donors. Our data indicate that such antibodies of IgM, IgA and/or IgG isotypes may occur in sera from patients with peripheral neuropathy of different aetiology and lacking M-protein as well as in healthy subjects, thereby casting doubts to the possible primary pathogenetic importance of such antibodies in neuropathy.

Materials and methods

Sera were obtained from 125 patients with peripheral neuropathy (table 1). Agarose electrophoresis or isoelectric focusing revealed monoclonal M-component in 16 patients who all had polyneuropathy. The M-component was of IgM isotype in 11 patients and IgG in five. Of the remaining
Occurrence of antibodies against peripheral nerve myelin from patients with peripheral neuropathy

Table 1 Survey of patients with neuropathy and blood donors for reactivity in ELISA with peripheral nerve myelin

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>No of patients</th>
<th>No with anti-peripheral nerve myelin reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polynuropathy and M-component</td>
<td></td>
<td>Total*  IgM  IgA  IgG</td>
</tr>
<tr>
<td>IgM isotype</td>
<td>11</td>
<td>8 7 3 1</td>
</tr>
<tr>
<td>IgG isotype</td>
<td>5</td>
<td>0 0 0 0</td>
</tr>
<tr>
<td>Waldenström disease without neuropathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and M-component of IgM isotype</td>
<td>12</td>
<td>0 0 0 0</td>
</tr>
<tr>
<td>Neuropathy without M-component</td>
<td>109</td>
<td>19 13 4 6</td>
</tr>
<tr>
<td>Guillain-Barré syndrome</td>
<td>14</td>
<td>2 1 1 1</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>12</td>
<td>1 1 0 0</td>
</tr>
<tr>
<td>Charcot-Marie-Tooth disease</td>
<td>10</td>
<td>5 4 0 1</td>
</tr>
<tr>
<td>Vitamin deficiency</td>
<td>3</td>
<td>2 1 0 0</td>
</tr>
<tr>
<td>Shoulder neuritis</td>
<td>3</td>
<td>1 1 0 0</td>
</tr>
<tr>
<td>Lyme disease</td>
<td>2</td>
<td>1 1 0 0</td>
</tr>
<tr>
<td>Paraneoplastic polyneuropathy</td>
<td>2</td>
<td>1 1 0 0</td>
</tr>
<tr>
<td>Neuropathy of other known causes</td>
<td>13</td>
<td>2 2 0 0</td>
</tr>
<tr>
<td>Neuropathy of unknown cause</td>
<td>40</td>
<td>4 1 2 3</td>
</tr>
<tr>
<td>Blood donors</td>
<td>142</td>
<td>23 11 16 11</td>
</tr>
</tbody>
</table>

*Some subjects had antibodies of more than one isotype.

109 patients, 90 had neuropathy, 14 Guillain-Barré syndrome, three shoulder neuritis and two polyradiculitis secondary to Borrelia burgdorferi infection. Sera were also obtained from 12 patients with Waldenström's disease and monoclonal serum IgM but no signs or symptoms of neuropathy, and from 142 blood donors who all denied polyneuropathy symptoms in a detailed questionnaire. The age of the blood donors (56 females) was 20–62 years (mean 38). Clinically overt polyneuropathy was assumed to exist when two of the following signs were demonstrable: Distal bilateral sensory impairment, distal bilateral muscle weakness and wasting, bilateral decrease or loss of tendon reflexes. Possible effects of aging on these variables were considered. All polyneuropathy patients were thoroughly evaluated, including a battery of blood and urine tests, and in most cases also chest radiography, neurophysiological and cerebrospinal fluid analysis.

Bovine PNM was prepared from lumbosacral plexus. It has previously been shown that human anti-myelin antibodies react with myelin of human as well as bovine origin.7–10

The ELISA used for detection of anti PNM antibodies has been described elsewhere.11 In brief, microtitre plates (Polyvinyl Chloride Microtitration plates, Virginia, USA) were coated with 0.1 ml/well of bovine PNM (80 μg/ml) in 0.05M sodium carbonate buffer pH 9.6 and incubated over-night at 4°C. Thereafter, the plates were incubated with 100 μl of phosphate buffered saline pH 7.2 containing 0.05% Tween 20 and 5% of bovine serum albumin (BSA) for 2 hours at room temperature. Patient sera were incubated for 90 minutes at 37°C in the same buffer solution. Optimal discrimination between antibody positive and negative samples was seen at dilutions of sera to concentrations of 15 mg/l for IgM and 10 mg/l for IgG and IgA. After incubation of samples and washings, the wells were incubated with alkaline phosphatase conjugated high affinity purified rabbit anti-human IgG, IgM or IgA antisera. Control samples, negative and positive for antibody were included on each plate and consisted of (A) pooled serum from 200 blood donors; (B) sera from patients with serum M-component of IgG, IgA and IgM class, respectively, but without polyneuropathy; (C) sera from patients with polyneuropathy and previously demonstrated IgG, IgA and IgM antibody activity against bovine PNM. Arbitrarily, anti-PNM antibodies were considered to be present when absorbance exceeded that of pooled normal serum by 0.2 units.

For Western blot, PNM was separated by sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred electrophoretically to nitrocellulose membranes.12,13 Electroblotting was performed in Trans-Blot Cell equipment (Bio Rad, Ca, USA) at a constant current of 0.1 A during 16 hours at 4°C. Separation gels contained no proteins after this transfer as shown by Coomassie blue staining. The blots were cut into 4–5 mm strips and incubated for 2 h in 5% (w/v) bovine serum albumin/10M Tris-HC1/0.9% NaCl, pH 7.6, to avoid unspecific binding to the possible empty space on the nitrocellulose membrane and overnight at room temperature in patients' serum diluted 1:100. After several washings in Tris saline buffer, the blots were incubated in a 1:500 dilution of high affinity purified goat anti-human IgG, IgM or IgA antisera. In order to increase sensitivity for antibody detection, secondary immunolabelling included an avidin-biotin peroxidase procedure.14,15 Controls consisted of pooled blood donor serum and sera from patients with serum M-component but without polyneuropathy and no antibodies against PNM as documented by ELISA. Inspection of strips for antibody binding was performed without knowledge of identity of the patient sample.

Results

Antibodies against PNM were found by ELISA in serum from eight of 11 patients with polyneuropathy and IgM M-component, and in none of five with IgG M-component (table 1). The anti-PNM antibodies were restricted to the IgM isotype in five patients, while two had such antibodies both of IgM and IgA isotype. The remaining patient showed anti-PNM antibodies of both IgA and IgG isotype. Using Western blot, presence, specificity and isotype of serum antibodies was confirmed in four of these patients, while
three showed discordant results regarding isotype in ELISA and Western blot, and one was negative in Western blot.

In the group of 12 patients with Waldenström disease, ELISA did not reveal serum antibodies against PNM.

Among the 109 neuropathy patients without serum M-component, ELISA revealed antibodies against PNM of one or more isotypes in 19 (17%). Among these antibody-positive patients, two had Guillain-Barré syndrome, one each had Lyme disease and shoulder neuritis, while the remaining 15 had polyneuropathy (table 1). Interestingly, Charcot-Marie-Tooth disease was diagnosed in five of these patients. The antibodies were of IgM isotypes in 13 patients, IgG in six and IgA in four. Thus, four of the patients had in their sera anti-PNM antibodies belonging to two of the three isotypes analysed. One had Guillain-Barré syndrome, one vitamin B₁₂ deficiency and two had polyneuropathy of unknown cause. Serum from 15 of the patients being positive in ELISA were available for Western blot and seven of them showed concordance with both methods.

Twenty three (16%) of the 142 blood donors also had anti-PNM antibodies as revealed by ELISA. In 13 patients, these antibodies belonged to one isotype, in five to two different isotypes and in five to three isotypes. IgA antibodies were found most frequently, followed by antibodies of IgG and IgM isotype. Western blot carried out on 14 ELISA positive sera confirmed presence of anti-PNM antibodies, and in 10 of them there was concordance between ELISA and Western blot results.

A 25–30 kD protein was found to be the target antigen for IgM as well as for IgA anti-PNM antibodies in all three groups of patients. A 100 kD antigen was also identified in the group of polyneuropathy patients who all lacked a serum M-component, and in the blood donors. In addition, three of the blood donors and two of the polyneuropathy patients without serum M-component displayed antibody binding to both target antigens. A survey of epitope reactivities is presented in table 2, and exemplified in fig 1. A higher rate of confirmation of ELISA data with
Occurrence of antibodies against peripheral nerve myelin from patients with peripheral neuropathy

Table 2: Survey of subjects with antibody binding to target antigens found by Western blot

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>25-30 kD protein</th>
<th>100 kD protein</th>
<th>(25-30) and 100 kD protein</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IgM</td>
<td>IgA</td>
<td>IgG</td>
</tr>
<tr>
<td>Polyneuropathy with serum M-component</td>
<td>6</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Neuropathy without serum M-component</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Blood donors</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Western blot findings was obtained for IgM isotype than IgA and IgG. Notably, several of the ELISA absorbance values registered among blood donors exceeded many of the values noticed among the patients with polyneuropathy and M-component. (fig 2).

Discussion

Our data show that occurrence of serum antibodies against PNM is not restricted to patients with polyneuropathy and paraproteinaemia, but can also be demonstrated in patients with polyneuropathy of different aetiology and lacking serum M-component, and in healthy controls. Quantities of antibodies as measured by ELISA, isotype of the PNM antibodies or target antigen did not clearly differ between these three groups. Therefore, any primary pathogenic role of these antibodies is doubtful. However, harmful effects of the antibodies may still occur in presence of damaged blood nerve barrier and/or inflammation within the peripheral nervous system.

A complete homology for the presence of anti-PNM antibodies of different isotypes between the results with ELISA and Western blot was recorded in slightly more than half of the subjects tested. The discrepancies observed might be explained by differences in antibody binding to different or changed epitopes in the two assays, as well as possible alter-
The excellent technical assistance of Mrs Lola Björkqvist, Mrs Monica Dufmats, and Mrs Christina Ekefeldt is gratefully acknowledged. We thank Ms Yvonne Nilsson for preparation of the manuscript.

This study was supported by grants from the Swedish Medical Research Council (projects No. 3381 and 7488), and the Swedish Society for Disabled.

References

14 Olsson T, Kostulas V, Link H. Improved detection of oligoclonal IgG in cerebrospinal fluid by agarose isoelectric focusing, double-antibody peroxidase and...
Occurrence of antibodies against peripheral nerve myelin from patients with peripheral neuropathy


